Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Enlivex Ltd.Bullish
Enlivex has announced a 1-for-16 reverse share split of its ordinary shares, effective October 27, 2026. Following this action, the number of issued and outstanding shares will decrease from approximately 24.51 million to 1.53 million, with the par value per share increasing from NIS 6.00 to NIS 96.00. The shares will continue to trade under the ticker symbol 'ENLV'.…more
Enlivex Ltd.
Enlivex has announced an immediate cost reduction plan to minimize cash burn and focus resources on the Phase 2b clinical trial of its knee osteoarthritis treatment, Allocetra. The restructuring includes a 60% workforce reduction, salary cuts for management and the CEO, and the wind-down of all non-clinical R&D activities. The company expects to report topline six-month data from the Phase 2b trial by mid-2027.…more
Enlivex Ltd.
Enlivex Ltd. will hold an Extraordinary General Meeting of Shareholders on October 16, 2026, to vote on a reverse share split proposal. The proposal includes a primary reverse split at a ratio between 1-for-13 and 1-for-16, and authorizes the Board to implement additional reverse splits within a 1-for-2 to 1-for-1,000 range over the following 12 months.…more
30 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
Enlivex Announces 1-for-16 Reverse Share Split
Enlivex is implementing a 1-for-16 reverse stock split to maintain compliance with Nasdaq listing requirements. While the split does not change the company's fundamental value, it is often a response to declining share prices.…more
●●●●●●●● ●●●●● ●●●●●●
Enlivex is cutting its workforce by 60% and winding down non-clinical R&D to focus resources on its Phase 2b clinical trial. The company aims to reduce cash burn and expects to report topline data from the trial by mid-2027.…more
●●●●●●●● ●●●●● ●●●●●●
Enlivex has announced the termination of its agreement to issue 66,666,667 shares in a private placement to the Rain Foundation. While this cancels the potential dilution of shares, investors should monitor the impact on the company's capital strategy.…more
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.